Investigating COVID-19 dynamics with individual-based models

NORDITA Francesco Di Ruscio



Pandemic response at NIPH

Situational awareness

- Forecast of epidemiological indicators
- Methods: SEIR models with changepoints SMC-ABC, SMC
- 150+ reports

Scenarios analyses

Pharmaceutical interventions

- National vs. Regional vaccine distribution
- Age and risk-group prioritization
- Vaccination of children (12-15)
- Increase uptake

Non-pharmaceutical interventions

- Individual behaviour (e.g. self-isolation)
- Quarantine measures
- Lockdowns

Epidemiological uncertainties

- New variants
- Seasonal effects

40. Oppdrag 610 - New strategy and preparedness plan Evaluating COVID-19 modelling Oppdrag 37: Vaccination of 16-17 years - Oppdrag-scenarios Holden IV - part I Oppdrag 16-revised: Vaccination strat Oppdrag 530: Border restrictions Oppdrag 8: reg prioritisation main report Holden IV main report Oppdrag 21: AZ vaccine to 65+ population Oppdrag 618: Mandatory isolation - sick leave Oppdrag 58: Vaccination of children of Recomm/priorities COVID-19 vacc part II Oppdrag 320: Alpha variant - proposes reports Oppdrag 611; Sick leave Oppdrag 45: Vaccination of 12-15years Holden III - part I Holden III - p number of modelling Oppdrag 28: AZ Expert group m Note - Effect of vacc MPM/IBM Extending Christmas break/vacation Oppdrag 473: Reopening when 18+years vaccinated oppdrag 346: Reopening sce Tild-brev 4-4 part III: vacc scenarios Oppdrag 8: reg provitisation Oslo part I Oppdrag 16: Revised geographic prioritisation Tild-brev 4-4 part I: vaco Recomm/priorities COVID-19 vacc part Cum. Note -Effect of vacc - prelim results Oppdrag 8: reg prioritisation Oslo/Viken part I Holden I Tild-brev 4-4 part II: vacc scena Risk, prognosis and response after week 12 Response to Corona commisi 0 des 2020 apr 2021 aug 2021 okt 2021 des 2021 apr 2020 jun 2020 aug 2020 okt 2020 feb 2021 jun 2021 feb 2022 apr 2022 jun 2022 Date

Mathematical models

- Meta-population model (MPM)
- Individual-based model (IBM)

FHI MODELLING WEB PAGE:

https://www.fhi.no/en/id/infectious-diseases/coronavirus/coronavirusmodelling-at-the-niph-fhi/

IBM structure


Norwegian IBM: Geo-spatial features

Gridded population data

Version 1 (GPW data)

- Approximately 5.4 mln individuals
- 4978 cells







Norwegian IBM: Geo-spatial features

Gridded population data


Version 2 (Statistics Norway data)

- Approximately 5.4 mln individuals
- 13521 cells, 356 municipalities / 11 counties





Norwegian IBM: Synthetic population





Census data (SSB, FHI)

Algorithm to build households (hhs):


- 1. Sample hh size from the distribution
- 2. Sample the age of the hh head from the age-distribution of that hh size
- 3. Define if there are more adults or kids in the hh
- 4. Sample the age of the other members

Household size by age






Individuals, settings and mobility




School holidays and home office

School holidays



0.8 Region 0.6 Agder Innlandet Møre.og.Romsdal Fraction Nordland Oslo 0.4 Rogaland Troms.og.Finnmark Trøndelag Vestfold.og.Telemark Vestland Viken 0.2

Home office (Google data)







5.3 mln individuals

Real socio-demography



Mobility patterns



Schools Workplaces Community




Hospitalizations

Epidemiological model

Synthetic population

Spread of AMR bacteria



Quantifying the transmission dynamics of MRSA in the community and healthcare settings in a low-prevalence country

Francesco Di Ruscio^{a,b,c}, Giorgio Guzzetta^d, Jørgen Vildershøj Bjørnholt^{e,f}, Truls Michael Leegaard^{c,e}, Aina Elisabeth Fossum Moen^{e,g}, Stefano Merler^d, and Birgitte Freiesleben de Blasio^{a,b,1}


^aDepartment of Infectious Disease Epidemiology and Modelling, Norwegian Institute of Public Health, 0456 Oslo, Norway; ^bDepartment of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, 0317 Oslo, Norway; ^cDepartment of Microbiology and Infection Control, Akershus University Hospital, 1478 Lørenskog, Norway; ^dCenter for Information Technology, Bruno Kessler Foundation, 38123 Trento, Italy; ^eInstitute of Clinical Medicine, University of Oslo, 0317 Oslo, Norway; ^fDepartment of Clinical Microbiology, Oslo University Hospital, 0317 Oslo, Norway; and ^gDepartment of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, 1478 Lørenskog, Norway

Edited by Burton H. Singer, University of Florida, Gainesville, FL, and approved June 3, 2019 (received for review January 24, 2019)

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a primarily nosocomial pathogen that, in recent years, has increasingly spread to the general population. The rising prevalence of MRSA in the community implies more frequent introductions in healthcare settings that could jeopardize the effectiveness of infection-control procedures. To investigate the epidemiological dynamics of MRSA in a low-prevalence country, we developed an individual-based model (IBM) reproducing the population's sociodemography, explicitly representing households, hospitals, and nursing homes. The model was calibrated to surveillance data from the Norwegian sufficient control combined with intensified international mobility, which are significantly contributing to the global spread of MRSA (9, 10). We currently have very limited knowledge of how the emerging community reservoir contributes to the local MRSA epidemiology in low-prevalence settings and to which degree it impacts the healthcare environments. The identification of the relationship between MRSA transmission within the healthcare settings and the community is of primary importance to tailor evidence-based preventive measures, which currently are largely healthcare centered.

An *in-silico* laboratory that we can use to study the transmission of different pathogens

COVID-19 epidemiological model




Main Parameters


- Gamma distributions transition time
- Transmission rates β (setting dependent)
- Susceptibilities by age
- Proportion of asymptomatics by age
- Relative infectiousness of P,I and A
- Risk of hospitalizations by age
- Risk of death by age
- LOS in hospital and ICU by age
- Vaccine efficacies + waning by dose and age


Total

> 100 parameters

Force of infection








ype 📕 Data 📕 Model

<u>Community</u>

We use a **negative binomial distribution** to take into account superspreading events. (Lloyd-Smith, Nature, 2005)

The model simulates age-dependent contacts in the community (based on Norwegian *contact data*) and *a spatial kernel* derived from mobility data from Telenor Norway.

Susceptibility factors capture behavioral changes in specific periods of time.





Vaccination model

Single shots of vaccine

Waning dynamics with different functional forms (linear, exponential)

Historical registry data (SYSVAK) used to initialize the model with the correct number of doses by age and municipality in time.





Model calibration

Computationally expensive stochastic model:

Simulation time: ~ 5-15 min (on a 2.6 GHz; programming language C)


Parameter exploration unfeasible with methods that rely upon large numbers of sequential model evaluations (e.g. MCMC).


HPC infrastructure are needed to run different simulations in parallel

Model calibration – Latin Hypercube Sampling


Data - e.g. hospital incidence

Set θ of free parameters - e.g. transmission rates β , susceptibility parameters






- Simulations can be run in parallel
- 10k -100k simulations –Computationally and financially expensive (HPC infrastructure needed).



Model calibration – *Emulators*

Given a set of model runs (training dataset) it is possible train an *emulator* (statistical model) and use it as a surrogate of the model, allowing for a more cost-effective exploration of the parameter space.



A retrospective study of the spread of the Omicron variant


(Preliminary results)


Omicron emergence - background

24 November 2021 First case detected in Norway from South Africa

Quick take over of the Omicron variant

Primary vaccination series completed Booster campaign started in October






Epidemiological model with 2 strains

Omicron vs. Delta

- Higher transmissibility, lower generation time
- Ability to evade natural immunity from previous infections
- Milder symptoms
- Lower vaccine efficacy against infection




Calibration

Refined VE values and other parameters from the litterature and Norwegian data


Free parameters (13):

- CTR : change in the ransmission rate due to inte
- β_1 : Transmissibility t₀:Oct 19th
- β_2 : Transmissibility from Oct 20th
- $\Delta_{omicron}$: Omicron advantage
- Sus : Susceptibility factors (9)


Data: incidence of hospitalization by age



Calibration – Emulation and history matching



Baseline




Omicron importation

The model suggests that the first Omicron cases arrived in Norway in the first weeks of November (earlier than the first detected cases).


"... Omicron was present in Europe 10 days before its discovery in South Africa ..."





- Timing of the booster dose
- Non-pharmaceutical interventions: timing of reopening the society
- School holidays
- Individual behavior


Timing of the booster dose




Lockdown and relaxation time of the control measures

10% reduction in the contact rate estimated

Scenario without the second dose





Reflections

The COVID-19 pandemic has provided an **unprecedented level data**.

IBMs are **data hungry models** that greatly benefit from the extensive information available in registries, as well as behavioral and mobility data from sources such as social media and telecommunication companies.


Retrospective analyses can give important insights into the spreading dynamics and the impacts of pharmaceutical and non-pharmaceutical interventions.

These insights are important for developing effective preparedness plans.

Vaccination strategy in Norway

Regional vs. national vaccination strategy





- Birgitte Freiesleben de Blasio Alfonso Diz-Lois Palomares Louis Yat Hin Chan
- Jonas Lindstrøm
- Jørgen Midtbø
- Anja Bråthen Kristoffersen
- Marissa Leblanc
- Francesco Di Ruscio
- Gunnar Øyvind Isaksson Rø
- Sasi Kandula
- Solveig Engebretsen Norsk Regnesentral
- Arnoldo Frigessi UiO
- Geir Storvik UiO
- Kenth Engø-Monsen Telenor Research



<image>









Thank you

francesco.diruscio@fhi.no